The efficacy and safety of Udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents

Journal of Sexual Medicine

Volumn 6, Issue 11, 2009, Pages 3166-3176

  Paick, Jae Seung ^a   Kim, Sae Woong ^b   Park, Yoon Kyu ^c   Hyun, Jae Seog ^d   Park, Nam Cheol ^e   Lee, Sung Won ^f   Park, Kwanjin ^a   Moon, Ki Hak ^g   Chung, Woo Sik ^h  

^a Seoul National University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Gyeongsang National University   (South Korea)

^e Pusan National University Hospital   (South Korea)

^f Samsung Medical Center   (South Korea)

^g Yeungnam University Hospital   (South Korea)

^h Mokdong Hospital   (South Korea)

Author keywords

Erectile dysfunction; Hypertension; Phosphodiesterase 5 inhibitor; Udenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; PLACEBO; UDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUSHING; HEART RATE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 70649084279     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01456.x     Document Type: Article

References (21)

1. Ahn TY, Park JK, Lee SW, Hong JH, Park NC, Kim JJ, Park K, Park H, Hyun JS. Prevalence and risk factors for erectile dysfunction in Korean men: Results of an epidemiological study. J Sex Med 2007, 4:1269-76.
2. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur Urol 2007, 51:75-88.
3. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007, 52:990-1005.
4. Mostafa T. Oral phosphodiesterase type 5 inhibitors: Nonerectogenic beneficial uses. J Sex Med 2008, 5:2502-18.
5. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006, 7:661-9.
6. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008, 5:946-53.
7. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek OR, Shabsigh R. Hypertension is associated with severe erectile dysfunction. J Urol 2000, 164:1188-91.
8. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: Prevalence and clinical correlates. Int J Impot Res 2000, 12:41-5.
9. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006, 2:447-55.
10. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005, 2:856-64.
11. Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, Mancia G. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: A randomized controlled trial. Am J Hypertens 2004, 17:1135-42.
12. Albuquerque DC, Miziara LJ, Saraiva JF, Rodrigues US, Ribeiro AB, Wajngarten M. Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. Int Braz J Urol 2005, 31:342-53.
13. Park HJ, Park NC, Shim HB, Park JK, Lee SW, Park K, Kim SW, Moon KH, Lee DH, Yoon SJ. An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008, 5:2405-13.
14. Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000, 18:1865-9.
15. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003, 92(9A):47M-57M.
16. Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005, 17:450-4.
17. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763-71.
18. Eardley I, Gentile V, Austoni E, Hackett G, Lembo D, Wang C, Beardsworth A. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004, 94:871-7.
19. Marumo K, Imaoka T, Fujimoto K, Watts S, Stothard D, McGill J. A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. J Sex Med 2007, 4:745-52.
20. Martínez-Jabaloyas JM, Gil-Salom M, Villamón-Fort R, Pastor-Hernández F, Martínez-García R, García-Sisamón F. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001, 40:641-6.
21. Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005, 95:366-70.